TIME Names Stablepharma's Fridge-Free Vaccine a best invention of 2026 16/10/2026 Healthcare Access to innovation Innovative drugs SPVX02 recognised in TIME's Medical & Healthcare category as Stablepharma advances its temperature-stable tetanus... Partners - STABLEPHARMA
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant 16/10/2026 Healthcare Innovative drugs International New patent allowances in South Korea, Mexico, New Zealand and the Philippines. Partners - Oryzon Genomics
Spain’s 53Biologics announces over €2m expansion to tackle high-demand stabilisation of ... 13/10/2026 Healthcare Innovative drugs New freeze-drying (lyophilisation) capability at Boecillo site, strengthens 53Biologics’ position as a key player in... Partners - 53Biologics
Asís Ariznavarreta is named Leader of the Market & Patient Access Unit at Outcomes’10 in S... 02/10/2026 Healthcare Access to innovation Innovative drugs His new role leading the Market & Patient Access unit at Outcomes’10 in Spain reinforces ProductLife Group’s commitment... Partners - ProductLife Group
ORYZON receives European Medicines Agency approval to initiate the HOPE-2 Phase II study ... 29/09/2026 Healthcare Rare diseases Innovative drugs PMS is a severely disabling genetic disorder related to autism. Partners - Oryzon Genomics
Investigar el cáncer con los pacientes: de destinatarios a parte activa de la investigació... 23/09/2026 Salud Acceso a la innovación Medicamentos innovadores Vanesa Abón Escalona, responsable del Programa Patient Advocacy AECC, explica cómo incorporar la experiencia de las... AseBio - Fundación Científica de la Asociación Española Contra el Cáncer
mRNA vaccines for the future of medicine 15/09/2026 Healthcare Coronavirus Innovative drugs The COVID-19 pandemic transformed mRNA technology into a large-scale clinical platform and demonstrated its ability to... Partners - GENESIS Biomed
ORYZON to participate in upcoming events in September and October 11/09/2026 Healthcare Innovative drugs International Oryzon Genomics will participate in several international investment and capital markets events in the United States and... Partners - Oryzon Genomics
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Sy... 10/09/2026 Healthcare Rare diseases Innovative drugs €3.1 million financing led by new investor Clave Capital, with participation from existing investors. Partners - CONNECTA THERAPEUTICS
#BIOSPAIN2026 | Abstract – Accelerating Cell & Gene Therapy Impact through analytical exce... 08/09/2026 Healthcare Innovative drugs Advanced therapies Cell and gene therapies are transforming biomedical innovation, but their development presents significant challenges in... Partners
